An interventional study of Tai Chi Exercise and Regular Exercise in Non-Alcoholic Fatty Liver Disease, sponsored by Fujian Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-05.
Sponsored by Fujian Provincial Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 53 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.
Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 13th largest by planned enrollment of the 89 interventional ones that give a count, is one of 13 that started in 2024, is one of 31 with no phase, reaches primary completion later than 28 of the 52 other live ones, and was the 120th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →42 of the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Liu Yan · Sites in China
Ages 18–65
The Affiliated Hospital of Hangzhou Normal University · Sites in China
Ages 65–100 · Healthy volunteers
Hudson Biotech · Sites in China
Ages 18–75
Eli Lilly and Company · Sites in China, United States, Argentina and 31 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 22 · Phase 3 7 · Phase 4 11
First in 2004; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 112 across the 89 interventional studies, 740 across the 54 observational. Of the 63 that completed or were terminated, 6 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 143 have an industry lead sponsor. The 10 most frequent:
Fujian Provincial Hospital is the lead sponsor of 41 studies on the registry; 23 are open to participants now.
Fujian Provincial Hospital has 1 study filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Non-alcoholic Fatty Liver Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06449833Zhujiang HospitalEffect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD | 2026-11 |
| NCT02863757Humanity and Health Research CentreFollow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease | 2026-12 |
| NCT06569524Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) | 2026-12 |
| NCT07099118Sunshine Lake Pharma Co., Ltd.A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects | 2026-12-30 |
| NCT06717828Fujian Provincial HospitalThe Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma. It is also implicated in the development of other metabolic dysfunction-related diseases. MAFLD has emerged as a growing public health concern in China. Despite its potential benefits, Tai Chi exercise has not been widely adopted for individuals with MAFLD, and there is limited research investigating its therapeutic efficacy. This study aims to evaluate the effects of a structured Tai Chi intervention on middle-aged and elderly individuals with MAFLD.
Methods: The study employs a comprehensive open, randomized, parallel, and controlled design. Eligible participants will be randomly allocated into three groups: Tai Chi, conventional exercise, and control. A total of 250 participants will be enrolled, comprising 100 participants each for the Tai Chi and conventional exercise groups and 50 for the control group. Both the Tai Chi and conventional exercise groups will participate in a structured 6-month exercise program. During the intervention, both groups will also receive regular health education on fatty liver disease. Participants will be encouraged to maintain their usual activities but will be advised against starting new exercise regimens. The control group will receive only health education on fatty liver disease. The primary efficacy endpoint is the change in hepatic triglyceride content measured via validated imaging techniques after 6 months. Secondary endpoints include changes in total body fat, waist circumference, body weight, blood pressure, blood lipids, blood glucose, insulin sensitivity, pancreatic beta-cell function, kidney function, and pulse wave velocity. Outcomes will be assessed at baseline and post-intervention.
Discussion: Tai Chi exercises demonstrate therapeutic potential in reducing intrahepatic fat content, promoting weight loss, and mitigating cardiovascular risk factors. Furthermore, their efficacy appears superior to that of conventional exercise modalities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tai Chi Exercise program, five times a week .
Behavioral: Tai Chi Exercise
Each exercise session lasts for 60 minutes, five days a week.
Behavioral: Regular Exercise
Conduct health education on fatty liver once every two months.
Behavioral: Control
Tai Chi is a moderate-intensity exercise suitable for middle-aged and elderly individuals. Participants will engage in the practice five times a week (three sessions will be in-person teaching, and two will be online), with each session lasting 60 minutes, continuing until the end of a six-month follow-up. Before the intervention begins, participants will receive a manual or instructional video on Tai Chi to understand its principles, practice techniques, and safety precautions. Each class will start with a warm-up and include a review of Tai Chi principles and movements, breathing techniques, and relaxation methods. Participants will document their Tai Chi practice over 24 weeks by submitting exercise weekly logs, while researchers will monitor their exercise progress weekly via phone using standardized forms to assess frequency, completion status, adverse events, and adherence.
The intervention for middle-aged and elderly individuals includes a combination of common activities: 15 minutes of walking, 15 minutes of body coordination activities (including limb movements and balance training), 15 minutes of muscle stretching, and 15 minutes of relaxation. Each exercise session lasts for 60 minutes, conducted five days a week. The heart rate during exercise will be adjusted based on monthly fitness assessments, and the daily activity level will be evaluated through logs and fitness trackers.
All participants will be advised not to change their existing lifestyle habits and will only receive health education related to fatty liver throughout the intervention. The educational methods will include large group sessions, individual education, and telephone follow-ups, conducted every two months. Additionally, dietary and exercise assessments will be carried out during the intervention, with dietary intake recorded using a three-day food diary to track daily calorie consumption.
Determination of Liver Fat Content
The liver is scanned using a SIEMENS 3.0T MRI (Magnetom Prisma, Siemens Healthineers, Germany). Participants lie supine, holding breath at end-expiration. A 3D multi-echo water-fat separation gradient echo sequence is used with parameters: TR 9.00 ms, TE1-6 at 1.05-7.38 ms, 4° flip angle, 450×394 mm FOV, 1.4×1.4×3.5 mm voxel size, 64 slices, 13 sec collection time. Images include in-phase, out-of-phase, water, fat, fat fraction, and R2\* relaxation. Liver fat content (%) is measured in pseudocolor mode. ROIs are selected in liver's left lobe, central right lobe, and posterior right lobe below the portal vein at two levels, each 4 cm², avoiding bile ducts and vessels. Average fat content from 9 ROIs represents total liver fat content.
Time frame: Baseline (month 0) to post-training (month 6)
Body weight
The measurement is conducted in the morning on an empty stomach, with advance notice given to participants.A standardized scale provided by the research center is placed on a flat surface.Participants are required to remove shoes, hats, and outerwear, and to wear only a single layer of clothing, removing any personal items such as wallets and phones.Participants stand calmly on the scale with their feet symmetrically positioned. Their bodies should be upright, arms naturally relaxed at their sides, head straight, and eyes looking forward.Measurements are taken twice, recording the average, ensuring that the discrepancy between the two measurements is less than 1.0 kg, with precision to 0.1 kg. Participants are advised to maintain an upright posture.
Time frame: Baseline (month 0) to post-training (month 6)
Waist circumference
Waist circumference is measured in the morning after fasting. Subjects must stand upright with relaxed abdomen, arms down, and feet together. Use a metric tape at the midpoint between the lower ribs and upper iliac crest (about 1 cm above the navel), wrapped snugly but not compressing the skin. Subjects should breathe normally with a relaxed abdomen, and the measurement is taken at the end of exhalation, avoiding abdominal muscle contraction or breath holding. Repeat twice and record the average, ensuring measurements differ by less than 2 cm, accurate to 0.1 cm.
Time frame: Time Frame: Baseline (month 0) to post-training (month 6)
Blood pressure
Subjects must avoid heavy exercise, training, eating, drinking (except water), caffeine, extreme temperatures, and blood pressure-altering meds before measuring. Stop smoking 30 min prior. Relax, empty bladder, rest 5 min. Measure BP in a comfortable room, seated naturally with back straight, palms up. Cuff on bare skin, 1-2 cm above inner elbow, not covering joint, tube aligned with middle finger. Cuff center at heart level. After one measurement, loosen cuff, let subject move arm slightly, then rest 1-2 min before next. Take three measurements, 1 min apart, to 1 mmHg precision.
Time frame: Baseline (month 0) to post-training (month 6)
Grip strength of both hands
Using a calibrated hand dynamometer (Brand: CAMRY, Model: EH101).Subjects may stand or sit with their upper limbs naturally hanging at their sides. The palm should face the inner side of the body, with the handle of the dynamometer facing outward.Subjects should grip the dynamometer firmly to measure their grip strength, maintaining a stable posture without swinging the dynamometer back and forth during the measurement.Measure three times and record the maximum value. The dynamometer should be reset to zero before each measurement. Values should be recorded with a precision of 0.1 kg. The measurement can be conducted in the order of right hand followed by left hand.
Time frame: Baseline (month 0) to post-training (month 6)
Body fat percentage
Using the BIA method, which calculates the proportion of fat and non-fat tissues based on the principle that well-hydrated tissues like muscles and blood vessels conduct electricity well, while fat tissue hardly conducts electricity at all.Measurements should be taken in a fasting state in the morning or more than 2 hours after a meal, with prior notification to the subjects; subjects should avoid vigorous exercise, saunas or baths, excessive alcohol consumption, and the intake of large amounts of water or food (1-2 hours before).Place the body fat analyzer (InBody 770, provided by the research center) on a flat, hard surface. The subject should stand barefoot on the foot electrodes of the body fat analyzer with dry skin, straighten the back and knees, raise the arms horizontally, extend the elbows, and position the arms at a 90° angle from the body with the palms pressed against the electrodes.Precision is to 0.1%.
Time frame: Baseline (month 0) to post-training (month 6)
Total body fat
To measure total body fat, a DEXA densitometer scans subcutaneous fat and body composition. Subjects wear minimal clothing, remove metals, and lie centered on the scanning bed, aligned with the midline. For wider bodies, a half-body scan is possible. The scan includes the head, spine, and one side of the body, with the head 3 cm below the bed's horizontal line. Hands are positioned thumbs up, palms to legs, and arms alongside the body. Nylon straps secure knees and feet. Start the scan from the toolbar, monitor the image for full body display, and reposition if needed. Composition results show fat percentage, and detailed reports are printed from the Reports dialog box.
Time frame: Baseline (month 0) to post-training (month 6)
Liver fibrosis scanning to determine liver stiffness
The FibroScan PRO-S by Echosens measures liver elasticity to assess hardness. Subjects lie supine with the right arm extended. Operators sit on the right, facing the subject and screen, placing the probe between ribs near the liver's right lobe, avoiding the edge. Use A-mode and M-mode to find a 6 cm deep, vascular-structure-free area, keeping the probe perpendicular to the skin. Press until the pressure indicator is green, then press the probe button for 1/10 sec data acquisition. Check the elastogram quality. For disinfection, end the exam, wipe off gel, and clean the probe tip with an alcohol-free disinfectant. Calibrate the probe every 12 months.
Time frame: Baseline (month 0) to post-training (month 6)
Abdominal visceral fat
Abdominal visceral fat measurement is performed using the SIEMENS 3.0T MRI instrument (Magnetom Prisma, Siemens Healthinners, Erlangen, Germany). During the examination, subjects lie in a supine position and hold their breath while a single-layer cross-sectional MRI scan is taken at the L4-L5 level. After the acquisition, Image J software is used to analyze the area of abdominal visceral fat.
Time frame: Baseline (month 0) to post-training (month 6)
Blood specimen
Lab tests include OGTT at 0, 30, 120 min, serum insulin at 0, 30, 120 min, HbA1c, lipids, liver and kidney function. Fasting blood is collected early morning by trained nurses. For OGTT (7-9 a.m.), subjects fast 8-10 hours and drink 75g anhydrous glucose in 300ml water (or 82.5g monohydrate) within 5 min. Blood samples are taken pre-test and at 30, 120 min post-glucose. Avoid tea, coffee, smoking, and heavy exercise. Samples are sent to Fujian Provincial Hospital lab for uniform testing, following standards and accredited.
Time frame: Baseline (month 0) to post-training (month 6)
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 25 months is close to that.
Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →
Fujian Provincial Hospital